TauRx announces completion of Phase 3 study enrolment for the first tau-based disease modifying treatment for Alzheimer’s disease

Aberdeen, Scotland and Singapore [January 11, 2021] – TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic. TauRx is pleased to be presenting its latest trial results at Biotech Showcase™ 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer’s disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.

Read more here